OBJECTIVES: We evaluated the efficacy of a hepatitis care coordination intervention to improve linkage to hepatitis A virus (HAV) and hepatitis B virus (HBV) vaccination and clinical evaluation of hepatitis C virus (HCV) infection among methadone maintenance patients. METHODS: We conducted a randomized controlled trial of 489 participants from methadone maintenance treatment programs in San Francisco, California, and New York City from February 2008 through June 2011. We randomized participants to a control arm (n = 245) and an intervention arm (n = 244), which included on-site screening, motivational-enhanced education and counseling, on-site vaccination, and case management services. RESULTS: Compared with the control group, intervention group participants were significantly more likely (odds ratio [OR] = 41.8; 95% confidence interval [CI] = 19.4, 90.0) to receive their first vaccine dose within 30 days and to receive an HCV evaluation within 6 months (OR = 4.10; 95% CI = 2.35, 7.17). A combined intervention adherence outcome that measured adherence to HAV-HBV vaccination, HCV evaluation, or both strongly favored the intervention group (OR = 8.70; 95% CI = 5.56, 13.61). CONCLUSIONS: Hepatitis care coordination was efficacious in increasing adherence to HAV-HBV vaccination and HCV clinical evaluation among methadone patients.
RCT Entities:
OBJECTIVES: We evaluated the efficacy of a hepatitis care coordination intervention to improve linkage to hepatitis A virus (HAV) and hepatitis B virus (HBV) vaccination and clinical evaluation of hepatitis C virus (HCV) infection among methadone maintenance patients. METHODS: We conducted a randomized controlled trial of 489 participants from methadone maintenance treatment programs in San Francisco, California, and New York City from February 2008 through June 2011. We randomized participants to a control arm (n = 245) and an intervention arm (n = 244), which included on-site screening, motivational-enhanced education and counseling, on-site vaccination, and case management services. RESULTS: Compared with the control group, intervention group participants were significantly more likely (odds ratio [OR] = 41.8; 95% confidence interval [CI] = 19.4, 90.0) to receive their first vaccine dose within 30 days and to receive an HCV evaluation within 6 months (OR = 4.10; 95% CI = 2.35, 7.17). A combined intervention adherence outcome that measured adherence to HAV-HBV vaccination, HCV evaluation, or both strongly favored the intervention group (OR = 8.70; 95% CI = 5.56, 13.61). CONCLUSIONS:Hepatitis care coordination was efficacious in increasing adherence to HAV-HBV vaccination and HCV clinical evaluation among methadonepatients.
Authors: Benjamin Lebwohl; Alfred I Neugut; Eliezer Stavsky; Sonia Villegas; Corinne Meli; Orlando Rodriguez; Carmen Franco; Marian S Krauskopf; Richard Rosenberg Journal: J Clin Gastroenterol Date: 2011 May-Jun Impact factor: 3.062
Authors: Catharina E A Lindenburg; Femke A E Lambers; Anouk T Urbanus; Janke Schinkel; Peter L M Jansen; Anneke Krol; Gerty Casteelen; Gerrit van Santen; Charlotte H S B van den Berg; Roel A Coutinho; Maria Prins; Christine J Weegink Journal: Eur J Gastroenterol Hepatol Date: 2011-01 Impact factor: 2.566
Authors: Paul Y Kwo; Eric J Lawitz; Jonathan McCone; Eugene R Schiff; John M Vierling; David Pound; Mitchell N Davis; Joseph S Galati; Stuart C Gordon; Natarajan Ravendhran; Lorenzo Rossaro; Frank H Anderson; Ira M Jacobson; Raymond Rubin; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Eirum Chaudhri; Janice K Albrecht Journal: Lancet Date: 2010-08-06 Impact factor: 79.321
Authors: John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir Journal: N Engl J Med Date: 2009-04-30 Impact factor: 91.245
Authors: Arlene C Seña; Sarah J Willis; Alison Hilton; Alexandria Anderson; David A Wohl; Christopher B Hurt; Andrew J Muir Journal: Public Health Rep Date: 2016 May-Jun Impact factor: 2.792
Authors: Oluwaseun Falade-Nwulia; Risha Irvin; Alana Merkow; Mark Sulkowski; Alexander Niculescu; Yngvild Olsen; Kenneth Stoller; David L Thomas; Carl Latkin; Shruti H Mehta Journal: J Subst Abuse Treat Date: 2019-01-30
Authors: Ruth Koepke; Danielle N Sill; Wajiha Z Akhtar; Kailynn P Mitchell; Sheila M Guilfoyle; Ryan P Westergaard; Stephanie L Schauer; James M Vergeront Journal: Public Health Rep Date: 2019-09-20 Impact factor: 2.792
Authors: Stacey B Trooskin; Joanna Poceta; Caitlin M Towey; Annajane Yolken; Jennifer S Rose; Najia L Luqman; Ta-Wanda L Preston; Philip A Chan; Curt Beckwith; Sophie C Feller; Hwajin Lee; Amy S Nunn Journal: J Gen Intern Med Date: 2015-02-14 Impact factor: 5.128
Authors: Ashly E Jordan; Don C Des Jarlais; Kamyar Arasteh; Courtney McKnight; Denis Nash; David C Perlman Journal: Drug Alcohol Depend Date: 2015-04-13 Impact factor: 4.492
Authors: Sandra E Larios; Carmen L Masson; Michael S Shopshire; Jennifer Hettema; Ashly E Jordan; Courtney McKnight; Christopher Young; Mandana Khalili; Randy M Seewald; Albert Min; Nicholas Hengl; James L Sorensen; Don C Des Jarlais; David C Perlman Journal: J Subst Abuse Treat Date: 2013-11-11
Authors: Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore Journal: Int J Drug Policy Date: 2015-07-17